Health policy news

European Medicines Agency: EMA has agreed three changes to human medicines for the treatment of cancer in February 2011.

Added: Tuesday 15 March 2011

New marketing authorisations - Docetaxel Teva Pharma (docetaxel) - Treatment of breast cancer, non-small-cell lung cancer and prostate cancer Withdrawal of marketing authorisation applications - Topotecan SUN (topotecan) - Intended for the treatment of metastatic cancer of the ovary, small-cell lung cancer and cervical cancer Arbitration procedures (non-safety related) - Docetaxel Teva Generics (docetaxel) - Treatment of: breast cancer, non-small-cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer More details can be found at:

+  http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/q_and_a/q_and_a_detail_000110.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac05802ae438


//